Cost-effectiveness of one month of daily isoniazid and rifapentine versus three months of weekly isoniazid and rifapentine for prevention of tuberculosis among people receiving antiretroviral therapy in Uganda.

Olivia FergusonYoungji JoJeff PenningtonKarl JohnsonRichard E ChaissonGavin ChurchyardDavid W Dowdy

Published in: Journal of the International AIDS Society (2021)

1HP has the potential to be cost-effective under many realistic circumstances. Cost-effectiveness depends on rifapentine price, relative completion and efficacy, prevalence of latent TB and local willingness-to-pay.

Keyphrases

mycobacterium tuberculosis
antiretroviral therapy
pulmonary tuberculosis
hiv aids
hiv infected
human immunodeficiency virus
hiv infected patients
risk factors
hiv positive
physical activity
health insurance
emergency department
human health
risk assessment